Dasatinib is a tyrosine kinase inhibitor, a type of chemotherapy drug, that functions as a potent senolytic. In a healthspan context, it selectively triggers apoptosis (programmed cell death) in senescent cells. These dysfunctional 'zombie' cells accumulate with age, driving chronic inflammation and tissue degradation, so their periodic removal is hypothesized to mitigate aspects of the aging process.
Verdict
A powerful but high-risk senolytic for the advanced and medically supervised.
HEALTHSPAN IMPACT
High Value
RISK LEVEL
High
EVIDENCE GRADE
B
MONTHLY COST
$300 - $800
Protocol
- Typically used intermittently with Quercetin (e.g., 100mg Dasatinib for 2-3 days monthly/quarterly).
Flags
- Requires a prescription and close medical supervision.
- Significant side effect profile including fatigue, fluid retention, and myelosuppression.
- Interacts with CYP3A4 inhibitors/inducers (e.g., grapefruit juice, St. John's Wort).
- Often used with Quercetin as part of the 'D+Q' senolytic protocol.
- Long-term safety of intermittent use for longevity is not yet established.